About Nabriva
Nabriva is a company based in Vienna (Austria) founded in 2006.. Nabriva has raised $193.08 million across 5 funding rounds from investors including Novartis, Hercules Capital and Orbimed. Nabriva has completed 1 acquisition, including Zavante. Nabriva offers products and services including XENLETA, CONTEPO, and SIVEXTRO. Nabriva operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Vienna, Austria
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nabriva Therapeutics Plc
-
Annual Revenue
$36.94 M27.82as on Dec 31, 2022
-
Net Profit
$-57.19 M-15.64as on Dec 31, 2022
-
EBITDA
$-55.27 M-14.74as on Dec 31, 2022
-
Total Equity Funding
$193.08 M (USD)
in 5 rounds
-
Latest Funding Round
$25 M (USD), Debt – Conventional
Dec 21, 2018
-
Investors
Novartis
& 9 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nabriva
Nabriva is a publicly listed company on the OTC with ticker symbol NBRVF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nabriva
Nabriva offers a comprehensive portfolio of products and services, including XENLETA, CONTEPO, and SIVEXTRO. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats serious bacterial infections in patients.
Addresses urinary tract and other infections.
Promoted for skin and soft tissue infections.
Unlock access to complete
Funding Insights of Nabriva
Nabriva has successfully raised a total of $193.08M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Debt – Conventional — $25.0M
-
First Round
First Round
(31 Jan 2006)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Debt – Conventional - Nabriva | Valuation |
investors |
|
| Jul, 2018 | Amount | Post-IPO - Nabriva | Valuation |
investors |
|
| Apr, 2015 | Amount | Series B - Nabriva | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nabriva
Nabriva has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Hercules Capital and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nabriva
Nabriva has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zavante. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
US-based, late clinical stage biotech developing IV Fosfomycin for cUTI and other MDR infections.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Nabriva
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nabriva Comparisons
Competitors of Nabriva
Nabriva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nabriva
Frequently Asked Questions about Nabriva
When was Nabriva founded?
Nabriva was founded in 2006.
Where is Nabriva located?
Nabriva is headquartered in Vienna, Austria.
Is Nabriva a funded company?
Nabriva is a funded company, having raised a total of $193.08M across 5 funding rounds to date. The company's 1st funding round was a Series B of $120M, raised on Jan 31, 2006.
What is the annual revenue of Nabriva?
Annual revenue of Nabriva is $36.94M as on Dec 31, 2022.
What does Nabriva do?
Nabriva Therapeutics is developing pleuromutilin class of antibiotics for MDR infections. Its lead product candidate is Lefamulin for treating acute bacterial skin and skin structure infections (phase II); intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) (FDA approved); for pediatric indications (phase I), STI, osteomyelitis, HABPVABP, and prosthetic joined infections (phase I). The antibiotic binds to a specific site on the bacterial ribosome responsible for bacterial protein synthesis. It has also developed Contepo (IV) for treating cUTI (NDAMAA filing) and pediatric indications (phase I).
Who are the top competitors of Nabriva?
Nabriva's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
What products or services does Nabriva offer?
Nabriva offers XENLETA, CONTEPO, and SIVEXTRO.
Is Nabriva publicly traded?
Yes, Nabriva is publicly traded on OTC under the ticker symbol NBRVF.
How many acquisitions has Nabriva made?
Nabriva has made 1 acquisition, including Zavante.
Who are Nabriva's investors?
Nabriva has 10 investors. Key investors include Novartis, Hercules Capital, Orbimed, HBM Healthcare Investments, and EcoR1.
What is Nabriva's ticker symbol?
The ticker symbol of Nabriva is NBRVF on OTC.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.